• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of plastic, reconstructive & aesthetic surgery: JPRAS >Treatment of infantile haemangiomas with atenolol: Comparison with a historical propranolol group
【24h】

Treatment of infantile haemangiomas with atenolol: Comparison with a historical propranolol group

机译：阿替洛尔治疗婴儿型血管瘤：与历史心得安组比较

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Propranolol, a lipophilic non-selective beta-blocker, has proven to be effective in the treatment of infantile haemangioma (IH). However, several side effects have been reported. Atenolol, a hydrophilic selective beta-1 blocker, could be an alternative and associated with fewer side effects. Thirty consecutive patients with IH were treated with atenolol between June 2010 and May 2011. The therapeutic effect was judged by clinical assessment and quantified by using a visual analogue scale (VAS) and the Haemangioma Activity Score (HAS). Side effects were also evaluated. The atenolol cohort was compared with a previously described cohort of 28 patients treated with propranolol between July 2008 and December 2009. Clinical involution was present in 90% (27/30) of the IH patients treated with atenolol. Mild side effects occurred in 40% (12/30) of these patients and severe side effects occurred in 3% (1/30). Compared with the previously described cohort treated with propranolol, mild side effects occurred in 50% (14/28) and severe side effects in 25% (7/28) of the patients (p = 0.04). Quantitative improvement of the IH in the atenolol group (n = 27) showed no significant difference in either the VAS score or the HAS compared to the propranolol group (n = 24). This study indicates that atenolol is effective in the treatment of IH. Compared with a historical control group treated with propranolol, the effects of atenolol seem to be similar and less frequently associated with severe side effects. Randomised clinical trials are necessary to evaluate the efficacy and safety of atenolol treatment in IH.
机译：普萘洛尔是一种亲脂性非选择性β受体阻滞剂，已被证明可有效治疗婴儿性血管瘤（IH）。然而，已经报道了几种副作用。阿替洛尔是一种亲水性选择性β-1阻滞剂，可能是一种替代品，并且副作用较少。在2010年6月至2011年5月之间，连续30例IH患者接受了阿替洛尔治疗。通过临床评估判断治疗效果，并使用视觉模拟量表（VAS）和血管瘤活性评分（HAS）进行量化。还评估了副作用。在2008年7月至2009年12月之间，将阿替洛尔队列与先前描述的28名接受普萘洛尔治疗的患者队列进行了比较。在接受阿替洛尔治疗的IH患者中，有90％（27/30）出现临床复旧。这些患者中有40％（12/30）发生轻度副作用，而3％（1/30）发生严重副作用。与先前所述的使用心得安进行治疗的队列比较，在50％（14/28）的患者中出现轻度副作用，在25％（7/28）的患者中出现严重的副作用（p = 0.04）。与普萘洛尔组（n = 24）相比，阿替洛尔组（n = 27）中IH的定量改善显示，VAS评分或HAS均无显着差异。这项研究表明阿替洛尔在治疗IH中有效。与使用普萘洛尔治疗的历史对照组相比，阿替洛尔的作用似乎相似，并且与严重副作用的发生频率较低。随机临床试验对于评估IH中阿替洛尔治疗的有效性和安全性是必要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号